JP2011513196A - ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのkcnqカリウムチャネル開口薬の使用 - Google Patents

ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのkcnqカリウムチャネル開口薬の使用 Download PDF

Info

Publication number
JP2011513196A
JP2011513196A JP2010518498A JP2010518498A JP2011513196A JP 2011513196 A JP2011513196 A JP 2011513196A JP 2010518498 A JP2010518498 A JP 2010518498A JP 2010518498 A JP2010518498 A JP 2010518498A JP 2011513196 A JP2011513196 A JP 2011513196A
Authority
JP
Japan
Prior art keywords
phenyl
keni
amino
methyl
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2010518498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011513196A5 (enExample
Inventor
バク−イェンセン・ヘンリエッテ・フスム
ヘルテル・クラウス・ペーター
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2011513196(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2011513196A publication Critical patent/JP2011513196A/ja
Publication of JP2011513196A5 publication Critical patent/JP2011513196A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010518498A 2007-08-01 2008-07-31 ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのkcnqカリウムチャネル開口薬の使用 Ceased JP2011513196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95330807P 2007-08-01 2007-08-01
DKPA200701110 2007-08-01
PCT/DK2008/050191 WO2009015667A1 (en) 2007-08-01 2008-07-31 Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted

Publications (2)

Publication Number Publication Date
JP2011513196A true JP2011513196A (ja) 2011-04-28
JP2011513196A5 JP2011513196A5 (enExample) 2011-07-21

Family

ID=39810209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010518498A Ceased JP2011513196A (ja) 2007-08-01 2008-07-31 ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのkcnqカリウムチャネル開口薬の使用

Country Status (17)

Country Link
US (1) US20100256145A1 (enExample)
EP (1) EP2185149A1 (enExample)
JP (1) JP2011513196A (enExample)
KR (1) KR20100050502A (enExample)
CN (1) CN101790374A (enExample)
AR (1) AR070513A1 (enExample)
AU (1) AU2008281112A1 (enExample)
BR (1) BRPI0814180A2 (enExample)
CA (1) CA2694887A1 (enExample)
CL (1) CL2008002273A1 (enExample)
EA (1) EA201070189A1 (enExample)
MX (1) MX2010001171A (enExample)
NZ (1) NZ582942A (enExample)
TW (1) TW200920350A (enExample)
UA (1) UA97847C2 (enExample)
WO (1) WO2009015667A1 (enExample)
ZA (1) ZA201000129B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540051A (ja) * 2013-12-02 2016-12-22 ケモセントリックス,インコーポレイティド Ccr6化合物
JP2018048143A (ja) * 2014-10-24 2018-03-29 小野薬品工業株式会社 Kcnq2〜5チャネル活性化剤
JP2019518754A (ja) * 2016-06-10 2019-07-04 サイフルーア ライフ サイエンシズ インコーポレイテッド フッ素化2−アミノ−4−(置換アミノ)フェニルカルバメート誘導体
JP2021525241A (ja) * 2018-05-22 2021-09-24 シャンハイ ジムン バイオファーマ, インコーポレーテッドShanghai Zhimeng Biopharma Inc. カリウムチャネル調節剤としてのp−ジアミノベンゼン誘導体、その製造方法およびその医薬における使用
JP2022553569A (ja) * 2019-11-08 2022-12-23 ゼノン・ファーマシューティカルズ・インコーポレイテッド うつ病性障害の治療方法
JP2025504538A (ja) * 2022-01-25 2025-02-12 シャンハイ ジムン バイオファーマ,インコーポレーテッド カリウムチャネル調節剤としてのアミド系化合物およびその製造と使用

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CA2715760C (en) * 2008-02-21 2017-06-13 Mitsubishi Tanabe Pharma Corporation Solid preparation for oral administration of cariprazine hydrochloride
DK2317852T3 (en) 2008-07-16 2015-03-23 Richter Gedeon Nyrt PHARMACEUTICAL FORMULATIONS CONTAINING dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
WO2010105189A1 (en) * 2009-03-12 2010-09-16 The Johns Hopkins University Method for identifying compounds that attenuate the function or reduce abundance of a voltage-gated potassium channel and are associated with maintenance of cognitive function in old age
US20120059037A1 (en) 2009-03-17 2012-03-08 Neurosearch A/S Substituted pyridine derivatives and their medical use
DE102009013612A1 (de) * 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
BRPI1014545A2 (pt) * 2009-05-29 2016-04-05 Astellas Pharma Inc composição farmacêutica para prevenção e/ou tratamento de transtorno de déficit de atenção/hiperatividade
CA2796616A1 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
CA2804165C (en) 2010-07-08 2015-02-24 Pfizer Inc. Piperidinyl pyrimidine amides as kv7 potassium channel openers
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013159095A1 (en) * 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
CN103012381B (zh) * 2013-01-10 2015-01-07 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
WO2016077724A1 (en) * 2014-11-13 2016-05-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education (2-amino-4(arylamino)phenyl) carbamates
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
WO2017218337A1 (en) 2016-06-13 2017-12-21 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
SI3600309T1 (sl) 2017-03-28 2022-10-28 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
MA51881B1 (fr) 2018-02-20 2023-08-31 H Lundbeck As Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7
US10590067B2 (en) 2018-02-20 2020-03-17 H. Lundbeck A/S Alcohol derivatives of carboxamides as Kv7 potassium channel openers
TWI788325B (zh) * 2018-02-21 2023-01-01 丹麥商H 朗德貝克公司 作為Kv7鉀通道開放劑的醇衍生物
WO2019203951A1 (en) * 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
CN108707087B (zh) 2018-06-29 2020-10-16 河北医科大学 一种4-(对三氟甲基苄基)-3-氟-1,2,4三苯胺衍生物及其药物组合物与用途
CN108863893A (zh) * 2018-07-09 2018-11-23 湖南博隽生物医药有限公司 二氢吲哚类衍生物及其在药物中的应用
WO2020150136A1 (en) 2019-01-15 2020-07-23 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
US11524005B2 (en) 2019-02-19 2022-12-13 Gilead Sciences, Inc. Solid forms of FXR agonists
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
RS66130B1 (sr) 2019-08-02 2024-11-29 H Lundbeck As Derivati alkohola kao otvarači kv7 kalijumovih kanala
AR119521A1 (es) 2019-08-02 2021-12-22 H Lundbeck As DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7
CN119490430A (zh) 2019-08-02 2025-02-21 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
KR102643653B1 (ko) * 2020-11-13 2024-03-06 기초과학연구원 신규한 아미노방향족 화합물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
JP2024508660A (ja) 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬
CN118026880A (zh) * 2022-11-11 2024-05-14 华东师范大学 芳基酰胺化合物、包含其的药物组合物及其用途
TW202521516A (zh) * 2023-08-17 2025-06-01 加拿大商再諾製藥公司 氮雜環庚烷及吡咯啶化合物及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087754A1 (en) * 2004-03-12 2005-09-22 H. Lundbeck A/S Substituted morpholine and thiomorpholine derivatives
WO2006029623A1 (en) * 2004-09-13 2006-03-23 H. Lundbeck A/S Substituted aniline derivatives
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
WO2007065449A1 (en) * 2005-09-09 2007-06-14 H. Lundbeck A/S Pyrimidine derivatives and their use as kcnq potassium channels openers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (enExample) * 1990-07-14 1993-08-14 Asta Medica Ag
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
ATE380176T1 (de) * 1999-08-04 2007-12-15 Icagen Inc Benzanilide als öffner des kaliumkanals
CA2438868A1 (en) * 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
JP2004535413A (ja) * 2001-05-31 2004-11-25 ブリストル−マイヤーズ スクイブ カンパニー Kcnqカリウムチャンネルモジュレーターとしてのシンナミド誘導体
AU2003294442A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 3-heterocyclic benzylamide derivatives as potassium channel openers
US6933308B2 (en) * 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
NZ540446A (en) * 2002-12-27 2008-03-28 Lundbeck & Co As H 1,2,4-Triaminobenzene derivatives useful for treating disorders of the central nervous system
EP1603858A2 (en) * 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
JP2006520333A (ja) * 2003-03-14 2006-09-07 ハー・ルンドベック・アクチエゼルスカベット 置換されたアニリン誘導体
AU2004222626B2 (en) * 2003-03-21 2010-06-24 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
EP2554162A1 (en) * 2006-02-07 2013-02-06 H. Lundbeck A/S Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia
US20090318507A2 (en) * 2006-05-02 2009-12-24 Chris Rundfeldt Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087754A1 (en) * 2004-03-12 2005-09-22 H. Lundbeck A/S Substituted morpholine and thiomorpholine derivatives
WO2006029623A1 (en) * 2004-09-13 2006-03-23 H. Lundbeck A/S Substituted aniline derivatives
WO2006092143A1 (en) * 2005-03-03 2006-09-08 H. Lundbeck A/S Substituted pyridine derivatives
WO2007065449A1 (en) * 2005-09-09 2007-06-14 H. Lundbeck A/S Pyrimidine derivatives and their use as kcnq potassium channels openers

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540051A (ja) * 2013-12-02 2016-12-22 ケモセントリックス,インコーポレイティド Ccr6化合物
US10786494B2 (en) 2013-12-02 2020-09-29 Chemocentryx, Inc. CCR6 compounds
JP2018048143A (ja) * 2014-10-24 2018-03-29 小野薬品工業株式会社 Kcnq2〜5チャネル活性化剤
US10676438B2 (en) 2014-10-24 2020-06-09 Ono Pharmaceutical Co., Ltd. KCNQ2-5 channel activator
JP2019518754A (ja) * 2016-06-10 2019-07-04 サイフルーア ライフ サイエンシズ インコーポレイテッド フッ素化2−アミノ−4−(置換アミノ)フェニルカルバメート誘導体
JP2021525241A (ja) * 2018-05-22 2021-09-24 シャンハイ ジムン バイオファーマ, インコーポレーテッドShanghai Zhimeng Biopharma Inc. カリウムチャネル調節剤としてのp−ジアミノベンゼン誘導体、その製造方法およびその医薬における使用
JP7294681B2 (ja) 2018-05-22 2023-06-20 シャンハイ ジムン バイオファーマ,インコーポレーテッド カリウムチャネル調節剤としてのp-ジアミノベンゼン誘導体、その製造方法およびその医薬における使用
JP2022553569A (ja) * 2019-11-08 2022-12-23 ゼノン・ファーマシューティカルズ・インコーポレイテッド うつ病性障害の治療方法
JP2025504538A (ja) * 2022-01-25 2025-02-12 シャンハイ ジムン バイオファーマ,インコーポレーテッド カリウムチャネル調節剤としてのアミド系化合物およびその製造と使用

Also Published As

Publication number Publication date
CN101790374A (zh) 2010-07-28
UA97847C2 (ru) 2012-03-26
CA2694887A1 (en) 2009-02-05
AR070513A1 (es) 2010-04-14
WO2009015667A1 (en) 2009-02-05
US20100256145A1 (en) 2010-10-07
BRPI0814180A2 (pt) 2015-01-27
EA201070189A1 (ru) 2010-08-30
MX2010001171A (es) 2010-03-01
AU2008281112A1 (en) 2009-02-05
TW200920350A (en) 2009-05-16
CL2008002273A1 (es) 2009-07-17
ZA201000129B (en) 2011-04-28
EP2185149A1 (en) 2010-05-19
NZ582942A (en) 2011-09-30
KR20100050502A (ko) 2010-05-13

Similar Documents

Publication Publication Date Title
JP2011513196A (ja) ドーパミン作動系が破壊された障害もしくは状態の症状を軽減するためまたはその障害もしくは状態を処置するためのkcnqカリウムチャネル開口薬の使用
TWI453013B (zh) N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
JP2021181465A (ja) レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
KR20130101545A (ko) 운동 장애 치료를 위한 세로토닌 수용체 작용제의 조합
EP2729176A1 (en) The use of serotonin receptor agonists for treatment of movement disorders
JP2022031814A (ja) 不安障害を治療するための(2S)-1-[4-(3,4-ジクロロフェニル)ピペリジン-1-イル]-3-[2-(5-メチル-1,3,4-オキサジアゾール-2-イル)ベンゾ[b]フラン-4-イルオキシ]プロパン-2-オールまたはその代謝産物
CA3111433A1 (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
HK1146655A (en) Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
HK1129593B (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia
HK1129593A1 (en) Use of kcnq-opener for the preparation of a pharmaceutical composition for treating schizophrenia
HK1181676A (en) Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110606

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120202

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120222

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130205

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20130625